UAE Healthtech Startup BioSapien Expands Pre-Series A Funding to $7 Million

BioSapien, a UAE-based healthtech firm, has increased its pre-Series A funding round to $7 million, securing new investments from prominent backers, including Golden Gate Ventures through its MENA Fund.

Founded in 2018 by Khatija Ali, BioSapien previously raised $5.5 million in December with support from Global Ventures and Dara Holdings. The additional funding will support the company’s upcoming clinical trials for its innovative 3D-printed drug delivery platform, set to launch in Abu Dhabi in the second quarter of 2025.

With this capital boost, BioSapien aims to accelerate research and development, further advancing its mission to enhance global healthcare solutions. The company has set an ambitious target of treating over one million patients worldwide by 2035, leveraging advanced drug delivery technology to improve patient outcomes.